Skip to main content

Table 1 Patient characteristics

From: Prospective comparison of early interim 18F-FDG-PET with 18F-FLT-PET for predicting treatment response and survival in metastatic breast cancer

Patient Age
(yrs)
Primary or
Recurrent
Metastatic site Histologya ER/PR/HER-2a Ki-67a Gradea
1 59 Recurrent Bone, lymph node, other Ductal +/−/+ NA III
2 47 Recurrent Bone, lymph node Ductal +/+/− 10 I
3 40 Recurrent Lung, liver, lymph node Ductal +/+/− 5 II
4 27 Primary Lung, lymph node Ductal +/+/− 10 II
5 52 Recurrent Bone, lymph node Ductal +/−/− NA NA
6 50 Recurrent Bone, liver Ductal +/−/+ NA II
7 54 Recurrent Lung, lymph node Ductal −/−/− NA NA
8 62 Recurrent Bone, other Ductal −/−/− 30 III
9 37 Recurrent Bone Ductal +/+/− 40 II
10 48 Recurrent Bone Ductal +/+/− NA II
11 67 Primary Bone NST +/+/− 10 I
12 43 Recurrent Bone Ductal −/−/− NA III
13 55 Recurrent Lymph node NST +/+/+ NA NA
14 38 Recurrent Bone, lung, liver Ductal +/+/− NA N A
15 61 Primary Bone, lung NST +/+/− 30 II
16 59 Recurrent Bone Ductal +/−/− 10 III
17 52 Recurrent Bone Ductal +/+/+ NA NA
18 37 Recurrent Bone, lung, liver, other NST +/+/+ 50 III
19 50 Recurrent Bone Ductal +/−/− NA NA
20 59 Recurrent Other Ductal −/−/− 30 III
21 55 Recurrent Bone, lung, liver Ductal −/−/− 20 II
22 57 Recurrent Lymph node, other NST −/−/− 40 III
23 45 Recurrent Other NST +/+/− 15 NA
24 51 Recurrent Lung, liver Ductal +/+/+ 20 II
25 54 Recurrent Other NST −/−/− > 90 III
  1. a Acquired at diagnosis
  2. Abbreviations: ER estrogen receptor, PR progesterone receptor, HER-2 human epidermal growth factor receptor 2, NA not available, NST no special type